Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, examines the evolution of the oncology biosimilar space in this special episode of Not So Different to close out Global Biosimilars Week 2023.
On this episode, The Center for Biosimilars® we dive into the heart of the fourth annual Global Biosimilars Week. This event sheds light on the rapidly evolving landscape of biosimilars and their critical role in transforming the health care industry.
Now, you might be wondering, what is Global Biosimilars Week all about? Well, it's an annual social media awareness campaign hosted by the International Generic and Biosimilar Association (IGBA), where experts, thought leaders, and industry pioneers are invited to discuss the latest advancements, challenges, and breakthroughs in the realm of biosimilars. The significance of this week goes beyond the surface. It's a catalyst for fostering collaboration, driving awareness, and pushing the boundaries of innovation in biosimilar development. And today, we have a special guest who is at the forefront of this transformative wave in health care.
Joining us is Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health. As a returning guest on the podcast, Fran brings a wealth of experience and insights, particularly in the realm of oncology biosimilars—an area that holds immense promise for improving cancer care and making these crucial treatments more accessible. In fact, estimates project that the incidence of cancer is projected to surge to 30 million patients worldwide by the year 2040, underlying the need for more affordable treatment options for these patients.
In our conversation with Fran, we'll explore the dynamic landscape of oncology biosimilars, the challenges and opportunities in the growing biosimilar industry, and what we can expect on the horizon. So, buckle up for an enlightening discussion as we unravel the layers of biosimilars during this Global Biosimilars Week special.
Show notes
For more information on Global Biosimilars Week, click here.
To read our article series in honor of Global Biosimilars Week, you can check out part 1, part 2, and part 3 here.
To watch the webinar The Center for Biosimilars collaborated with IGBA for Global Biosimilars Week, click here.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
June 27th 2024Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.